Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Fengabine

From Wikipedia, the free encyclopedia
Fengabine
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • (6Z)-6-[butylamino-(2-chlorophenyl)methylene]-4-chloro-cyclohexa-2,4-dien-1-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC17H17Cl2NO
Molar mass322.23 g·mol−1

Fengabine (SL-79,229) is a drug which was investigated as an antidepressant but was never marketed.[1][2] Its mechanism of action is unknown, but its antidepressant effects are reversed by GABAA receptor antagonists like bicuculline and it has hence been labeled as GABAergic; however, it does not actually bind to GABA receptors, nor does it inhibit GABA-T.[1][2] In clinical trials, fengabine's efficacy was comparable to that of the tricyclic antidepressants, but with a more rapid onset of action and much less side effects.[3][4][5] Notably, fengabine lacks any sedative effects.[4]

See also

[edit]

References

[edit]
  1. 1 2 Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G (April 1987). "Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile". The Journal of Pharmacology and Experimental Therapeutics. 241 (1): 245–50. doi:10.1016/S0022-5347(25)00326-X. PMID 3033203.
  2. 1 2 Scatton B, Lloyd KG, Zivkovic B, et al. (April 1987). "Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat". The Journal of Pharmacology and Experimental Therapeutics. 241 (1): 251–7. doi:10.1016/S0022-5347(25)00327-1. PMID 3033204.
  3. Magni G, Garreau M, Orofiamma B, Palminteri R (1989). "Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics". Neuropsychobiology. 20 (3): 126–31. doi:10.1159/000118485. PMID 2668780.
  4. 1 2 Nielsen NP, Cesana B, Zizolfi S, Ascalone V, Priore P, Morselli PL (November 1990). "Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: a double-blind study versus clomipramine". Acta Psychiatrica Scandinavica. 82 (5): 366–71. doi:10.1111/j.1600-0447.1990.tb01402.x. PMID 2281807. S2CID 44534975.
  5. Fairweather DB, Kerr JS, Hilton S, Hindmarch I (March 1993). "A placebo controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers". British Journal of Clinical Pharmacology. 35 (3): 278–83. doi:10.1111/j.1365-2125.1993.tb05695.x. PMC 1381575. PMID 8471403.